Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene therapies and gene editing for the treatment of genetic diseases
Company stage: Pre-clinical
Diseases (gene editing): Primary Hyperoxaluria, undisclosed liver diseases
Genome editing tool: CRISPR-Cas13d, multiple novel CRISPR variants
Funding stage: Private
Location: Cambridge, MA, USA
Arbor Biotechnologies is a CRISPR-focused company that develops novel Cas variants for enhanced precision and efficacy. The company's lead programme is being developed for primary hyperoxaluria. The company is co-founded by CRISPR pioneer Feng Zhang and has established multiple collaborations, including but not limited to Vertex Pharmaceuticals and Vor Biopharma.